Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Hodgkin Disease 38Lymphoma 14Lymphoma, Large-Cell, Anaplastic 10Lymphoma, T-Cell 9Hematologic Diseases 8Lymphoma, Non-Hodgkin 7Lymphoma, T-Cell, Peripheral 6Lymphoma, Large B-Cell, Diffuse 5Mycosis Fungoides 4Lymphomatoid Papulosis 4Lymphoma, T-Cell, Cutaneous 4Enteropathy-Associated T-Cell Lymphoma 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 3Lymphoma, B-Cell 3Lymphatic Diseases 3Immunoblastic Lymphadenopathy 3Testicular Neoplasms 2Sezary Syndrome 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Embryonal 2Subcutaneous panniculitis-like T-cell lymphoma 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nonseminomatous germ cell tumor 1Neoplasms by Histologic Type 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Brentuximab Vedotin × Clear all
NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Seagen Inc.

Phase 2 Completed
161 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡